

## Supporting information

# Specific Phospholipid Modulation by Muscarinic Signaling in a Rat Lesion Model of Alzheimer's Disease

Alberto Llorente-Ovejero<sup>1</sup>, Jonatan Martínez-Gardeazabal<sup>1</sup>, Marta Moreno-Rodríguez<sup>1</sup>, Laura Lombardero<sup>1</sup>, Estíbaliz González de San Román<sup>1</sup>, Iván Manuel<sup>1,2</sup>, María Teresa Giralt<sup>1</sup>, Rafael Rodríguez-Puertas<sup>1,2 \*</sup>

<sup>1</sup>*Department of Pharmacology, Faculty of Medicine and Nursing. University of the Basque Country (UPV/EHU), B° Sarriena s/n, 48940 Leioa, Spain.*

<sup>2</sup>*Neurodegenerative Diseases, BioCruces Bizkaia Health Research Institute, Barakaldo, Spain.*

**Table S1.** Relative intensity of representative lipid species which have been found to be modified in the NBM and cortex of vehicle (aCSF) and 192IgG-saporin treated rats, in both positive and negative ion mode.

Assignment	Cal m/z	Exp m/z	% Intensity <sup>[1]</sup>				
			aCSF	NBM		Cortex	
				SAP	aCSF	SAP	
<b>Positive ion mode</b>							
PE (14:1/20:4) + H <sup>+</sup>	710.4755	710.4893	15.21 ± 0.70	<b>11.87 ± 1.38*</b>	9.97 ± 0.62	<b>10.67 ± 0.67</b>	
SM (d18:1/18:0) + H <sup>+</sup>	731.6061	731.6070	7.11 ± 1.13	<b>4.15 ± 0.80*</b>	4.19 ± 0.44	<b>3.50 ± 0.53</b>	
SM (d18:1/16:0) + K <sup>+</sup>	741.5313	741.5311	0.96 ± 0.14	<b>10.63 ± 3.33**</b>	0.55 ± 0.13	<b>0.78 ± 0.11</b>	
PC (32:0)+Na <sup>+</sup> /PC (34:3) + H <sup>+</sup>	756.5514	756.5520	15.75 ± 1.23	<b>21.94 ± 2.46*</b>	16.94 ± 1.02	<b>17.41 ± 1.31</b>	
PC (34:2)+Na <sup>+</sup> /PC (36:5) + H <sup>+</sup>	780.5514	780.5521	0.85 ± 0.09	<b>2.02 ± 0.27**</b>	1.10 ± 0.08	<b>1.07 ± 0.08</b>	
PC (34:1)+Na <sup>+</sup> /PC (36:4) + H <sup>+</sup>	782.5670	782.5673	32.75 ± 1.65	<b>46.10 ± 3.86**</b>	32.31 ± 1.64	<b>30.9 ± 1.29</b>	
PC (34:2) + K <sup>+</sup>	796.5253	796.5255	3.27 ± 0.17	<b>5.2 ± 0.30***</b>	4.20 ± 0.15	<b>4.16 ± 0.07</b>	
PC (34:1) + K <sup>+</sup>	798.5410	798.5405	100 ± 0	<b>100 ± 0</b>	100 ± 0	<b>100 ± 0</b>	
PC (36:4)+Na <sup>+</sup> /PC (38:7) + H <sup>+</sup>	804.5514	804.5510	2.79 ± 0.31	<b>7.69 ± 1.52*</b>	3.63 ± 0.31	<b>4.3 ± 0.24</b>	
PC (36:1)+Na <sup>+</sup> /PC (38:4) + H <sup>+</sup>	810.5983	810.5984	14.62 ± 0.30	<b>21.64 ± 1.53**</b>	10.62 ± 0.48	<b>8.95 ± 0.63*</b>	
PC (36:4) + K <sup>+</sup>	820.5253	820.5249	10.32 ± 1.01	<b>18.61 ± 2.71*</b>	13.17 ± 0.99	<b>15.63 ± 0.48*</b>	
PC (38:4)+Na <sup>+</sup> /PC (40:7) + H <sup>+</sup>	832.5827	832.5826	3.00 ± 0.30	<b>7.98 ± 1.40**</b>	2.82 ± 0.25	<b>3.11 ± 0.21</b>	
PC (38:4)+K <sup>+</sup> /PC (42:9) + H <sup>+</sup>	848.5566	848.5560	10.23 ± 0.93	<b>18.27 ± 2.15**</b>	9.71 ± 0.80	<b>10.75 ± 0.38</b>	
PC (40:6) + Na <sup>+</sup>	856.5827	856.5820	0.88 ± 0.17	<b>2.25 ± 0.40**</b>	0.75 ± 0.11	<b>1.14 ± 0.09*</b>	
<b>Negative ion mode</b>							
SM (d18:1/15:0) - H <sup>-</sup>	687.5447	687.5443	1.26 ± 0.24	<b>6.44 ± 1.50**</b>	0.94 ± 0.23	<b>1.52 ± 0.28</b>	
PS (18:0/18:1) - H <sup>-</sup>	788.5447	788.5447	11.04 ± 2.16	<b>3.95 ± 0.99**</b>	8.54 ± 1.28	<b>6.30 ± 0.85</b>	
PE (40:4)/PC (18:0/20:4) - H <sup>-</sup>	794.5705	794.5705	0.82 ± 0.13	<b>1.35 ± 0.17*</b>	0.83 ± 0.08	<b>0.98 ± 0.14</b>	
PG (22:6/22:6) - H <sup>-</sup>	865.5025	865.5033	0.06 ± 0.01	<b>0.86 ± 0.24**</b>	0.04 ± 0.01	<b>0.16 ± 0.05*</b>	

<sup>[1]</sup> The maximal peak is the most intense peak of the lipid spectrum, in this case PC (34:1) in positive and PI (20:4/18:0) in negative ion modes, which are set at 100%. Data are mean ± S.E.M values of aCSF (n = 8) and 192IgG-saporin-treated (n = 8) rats. \*p < 0.05, \*\*p < 0.01 and \*\*\*p < 0.001 when compared to aCSF group. PC: phosphatidylcholine; SM: sphingomyelin; PS: phosphatidylserine; PE: phosphatidylethanolamine; PG: phosphoglycerol; PI: phosphatidylinositol; Cal: calculated; Exp: experimental.

**Table S2.** [<sup>35</sup>S]GTP<sub>γ</sub>S basal and carbachol-induced (100 μM) binding in cortical, hippocampal and several brain regions of vehicle (aCSF) and 192IgG-saporin-treated rats.

Brain region	Basal binding (nCi/g t.e.)		Carbachol stimulation (% Over basal)	
	aCSF	SAP	aCSF	SAP
<b>Cerebral cortex</b>				
Cingulate	304 ± 26	306 ± 20	<b>52 ± 12.1</b>	<b>48 ± 6.7</b>
Ectorhinal	352 ± 34	290 ± 29	<b>66 ± 12.5</b>	<b>58 ± 8.0</b>
Entorhinal	342 ± 35	335 ± 36	<b>76 ± 10.5</b>	<b>93 ± 11.6</b>
Perirhinal	338 ± 49	309 ± 29	<b>35 ± 5.8</b>	<b>43 ± 3.5</b>
Somatosensory	355 ± 28	333 ± 20	<b>31 ± 7.0</b>	<b>54 ± 10.6</b>
Motor	311 ± 33	319 ± 20	<b>40 ± 13.3</b>	<b>66 ± 6.5</b>
<b>Hippocampus</b>				
CA1				
Oriens	320 ± 40	269 ± 32	<b>26 ± 9.4</b>	<b>40 ± 10.4</b>
Pyramidal	527 ± 64	457 ± 50	<b>40 ± 11.5</b>	<b>30 ± 6.2</b>
Radiatum	363 ± 33	323 ± 36	<b>45 ± 11.5</b>	<b>42 ± 9.0</b>
CA3				
Oriens	317 ± 26	303 ± 38	<b>26 ± 8.0</b>	<b>48 ± 6.6</b>
Pyramidal	477 ± 36	453 ± 42	<b>11 ± 5.6</b>	<b>32 ± 4.2*</b>
Radiatum	328 ± 21	281 ± 32	<b>28 ± 9.5</b>	<b>40 ± 13.0</b>
Dentate gyrus				
Granular	467 ± 29	452 ± 50	<b>24 ± 6.1</b>	<b>48 ± 9.7*</b>
Molecular	315 ± 49	278 ± 45	<b>34 ± 14.7</b>	<b>34 ± 9.5</b>
<i>Mesencephalon</i>				
Periaqueductal gray	496 ± 44	469 ± 45	<b>51 ± 15.0</b>	<b>47 ± 8.5</b>
Substantia nigra	456 ± 52	399 ± 38	<b>31 ± 10.5</b>	<b>37 ± 5.4</b>
<b>Basal ganglia/cholinergic forebrain</b>				
Globus pallidus	335 ± 43	347 ± 36	<b>46 ± 13.2</b>	<b>49 ± 12.5</b>
Striatum	339 ± 26	345 ± 21	<b>74 ± 15.4</b>	<b>62 ± 11.1</b>
NBM	535 ± 49	398 ± 31	<b>43 ± 9.2</b>	<b>11 ± 7.5*</b>
Horiz. diagonal band	310 ± 25	327 ± 31	<b>121 ± 20.7</b>	<b>115 ± 17.6</b>
Vertical diagonal band	330 ± 25	399 ± 42	<b>135 ± 24.1</b>	<b>113 ± 23.2</b>
Medial septum	267 ± 24	284 ± 32	<b>152 ± 24.4</b>	<b>139 ± 23.7</b>

Data are mean ± S.E. M values of aCSF (n = 9) and SAP (n = 11) treated rats.

\* p < 0.05, when compared to aCSF group.

**Table S3.** [<sup>35</sup>S]GTP $\gamma$ S basal and carbachol-induced (100  $\mu$ M) binding in the different amygdaloid nuclei and several brain regions of vehicle (aCSF) and 192IgG-saporin-treated rats.

Brain region	Basal binding (nCi/g t.e.)		Carbachol stimulation (% Over basal)	
	aCSF	SAP	aCSF	SAP
<i>Telencephalon</i>				
<b>Amygdaloid nuclei</b>				
Anterior	421 $\pm$ 33	402 $\pm$ 29	<b>59 <math>\pm</math> 9.1</b>	<b>47 <math>\pm</math> 13.6</b>
Basolateral	487 $\pm$ 47	390 $\pm$ 44	<b>43 <math>\pm</math> 6.6</b>	<b>48 <math>\pm</math> 10.9</b>
Central	710 $\pm$ 91	525 $\pm$ 55	<b>27 <math>\pm</math> 9.2</b>	<b>52 <math>\pm</math> 7.8</b>
Lateral	483 $\pm$ 50	425 $\pm$ 43	<b>41 <math>\pm</math> 9.3</b>	<b>36 <math>\pm</math> 7.2</b>
Medial	720 $\pm$ 94	621 $\pm$ 69	<b>39 <math>\pm</math> 8.5</b>	<b>34 <math>\pm</math> 4.7</b>
Ventral subiculum	345 $\pm$ 29	294 $\pm$ 18	<b>37 <math>\pm</math> 4.8</b>	<b>47 <math>\pm</math> 6.7</b>
<i>Rhinencephalon</i>				
Lat olfactory tract	379 $\pm$ 45	324 $\pm$ 37	<b>82 <math>\pm</math> 13.1</b>	<b>47 <math>\pm</math> 11.5</b>
<i>Midbrain</i>				
AV thalamic nucleus	425 $\pm$ 32	397 $\pm$ 41	<b>232 <math>\pm</math> 17.4</b>	<b>251 <math>\pm</math> 28.6</b>
Gray sup colliculus	341 $\pm$ 27	362 $\pm$ 36	<b>197 <math>\pm</math> 15.4</b>	<b>211 <math>\pm</math> 19.9</b>
<i>Rhomboencephalon</i>				
Dorsal raphe	703 $\pm$ 103	590 $\pm$ 74	<b>19 <math>\pm</math> 4.9</b>	<b>24 <math>\pm</math> 4.7</b>
Locus coeruleus	220 $\pm$ 36	132 $\pm$ 16	<b>26 <math>\pm</math> 11.9</b>	<b>78 <math>\pm</math> 11.9</b>

Data are mean  $\pm$  S.E. M values of aCSF (n = 9) and SAP (n = 11) treated rats.

**Table S4.** [<sup>35</sup>S]GTP $\gamma$ S basal and carbachol-induced (100  $\mu$ M) binding in different regions of grey matter from SHAM-operated rats.

	Basal binding (nCi/g t.e.)	Carbachol stimulation (% Over basal)		Basal binding (nCi/g t.e.)	Carbachol stimulation (% Over basal)
<b>Brain region</b>			<b>Brain region</b>		
<i>Telencephalon</i>			<b>Cerebral cortex</b>		
<b>Amygdala</b>			Cingulate	354 $\pm$ 30	<b>43 <math>\pm</math> 12.7</b>
Anterior	403 $\pm$ 33	<b>37 <math>\pm</math> 14.4</b>	Ectorhinal	337 $\pm$ 56	<b>36 <math>\pm</math> 6.5</b>
Basolateral	387 $\pm$ 41	<b>53 <math>\pm</math> 10.5</b>	Entorhinal	308 $\pm$ 30	<b>47 <math>\pm</math> 7.1</b>
Central	536 $\pm$ 53	<b>32 <math>\pm</math> 8.39</b>	Perirhinal	309 $\pm$ 43	<b>36 <math>\pm</math> 13.5</b>
Lateral	373 $\pm$ 53	<b>78 <math>\pm</math> 16.9</b>	Piriform	270 $\pm$ 31	<b>61 <math>\pm</math> 9.8</b>
Medial	672 $\pm$ 84	<b>34 <math>\pm</math> 11.7</b>	Somatosensory	368 $\pm$ 28	<b>34 <math>\pm</math> 4.9</b>
<b>Hippocampus</b>			Motor	353 $\pm$ 37	<b>34 <math>\pm</math> 14.8</b>
CA1			<b>Basal ganglia</b>		
Oriens	252 $\pm$ 25	<b>27 <math>\pm</math> 12.0</b>	Globus pallidus	275 $\pm$ 25	<b>54 <math>\pm</math> 12.2</b>
Pyramidal	366 $\pm$ 44	<b>55 <math>\pm</math> 15.6</b>	Striatum	330 $\pm$ 37	<b>85 <math>\pm</math> 14.0</b>
Radiatum	279 $\pm$ 19	<b>42 <math>\pm</math> 9.8</b>	<i>Diencephalon</i>		
CA3			NBM	492 $\pm$ 51	<b>47 <math>\pm</math> 12.3</b>
Oriens	280 $\pm$ 44	<b>21 <math>\pm</math> 6.8</b>	Horiz diag band	356 $\pm$ 29	<b>115 <math>\pm</math> 19.5</b>
Pyramidal	419 $\pm$ 52	<b>9 <math>\pm</math> 6.2</b>	Vertical diag band	366 $\pm$ 28	<b>112 <math>\pm</math> 25.6</b>
Radiatum	264 $\pm$ 38	<b>40 <math>\pm</math> 19.8</b>	Medial septum	280 $\pm$ 50	<b>150 <math>\pm</math> 41.2</b>
Dentate gyrus			<i>Rhinencephalon</i>		
Granular	437 $\pm$ 32	<b>25 <math>\pm</math> 1.2</b>	Lat olfactory tract	356 $\pm$ 27	<b>41 <math>\pm</math> 9.8</b>
Molecular	263 $\pm$ 45	<b>44 <math>\pm</math> 9.2</b>	<i>Rhomboencephalon</i>		
Polimorphic	290 $\pm$ 39	<b>28 <math>\pm</math> 15.7</b>	Dorsal raphe	533 $\pm$ 99	<b>42 <math>\pm</math> 9.4</b>
Vent subic	301 $\pm$ 35	<b>49 <math>\pm</math> 11.4</b>	Locus coeruleus	197 $\pm$ 30	<b>52 <math>\pm</math> 6.0</b>
<i>Brainstem</i>			<i>Mesencephalon</i>		
Spinal trig N	178 $\pm$ 25	<b>87 <math>\pm</math> 19.8</b>	Periaqueduc gray	450 $\pm$ 82	<b>47 <math>\pm</math> 10.3</b>
			Substantia nigra	361 $\pm$ 56	<b>32 <math>\pm</math> 14.9</b>

Data are mean  $\pm$  S.E. M values of SHAM-operated (n = 6) rats.

**Table S5.** [<sup>3</sup>H]-pirenzepine and [<sup>3</sup>H]-oxotremorine binding in different brain regions of vehicle (aCSF) and 192IgG-saporin-treated rats.

<b>[<sup>3</sup>H]-pirenzepine binding (fmol/mg t.e.)</b>			<b>[<sup>3</sup>H]-oxotremorine binding (fmol/mg t.e.)</b>		
<b>Brain region</b>	<b>aCSF</b>	<b>SAP</b>	<b>Brain region</b>	<b>aCSF</b>	<b>SAP</b>
<b>Amygdala</b>			<b>Amygdala</b>		
Anterior	7.3 ± 0.8	<b>3.6 ± 0.9*</b>	Anterior	21.2 ± 2.7	<b>31.1 ± 1.9</b>
Basolateral	70.2 ± 5.9	<b>74.5 ± 4.8</b>	Basolateral	5.2 ± 1.7	<b>5.1 ± 1.8</b>
Central	30.5 ± 3.6	<b>37.6 ± 6.6</b>	Lateral	5.4 ± 1.1	<b>5.3 ± 1.6</b>
Lateral	66.1 ± 6.2	<b>66.1 ± 4.8</b>	<b>Hippocampus</b>		
<b>Hippocampus</b>			CA1		
CA1	111.3 ± 10	<b>131.8 ± 8.8</b>	Pyramidal	6.2 ± 1.5	<b>7.5 ± 2.2</b>
Oriens	114.8 ± 10	<b>126.1 ± 4.2</b>	CA3		
Pyramidal	127.9 ± 9.7	<b>134.9 ± 7.9</b>	Pyramidal	11.0 ± 2.3	<b>11.3 ± 2.6</b>
Radiatum	120.6 ± 8.6	<b>136.2 ± 7.7</b>	Dentate gyrus		
CA3	58.2 ± 6.6	<b>64.1 ± 2.5</b>	Granular	3.6 ± 1.5	<b>7.1 ± 1.7</b>
Oriens	43.4 ± 3.4	<b>58.3 ± 2.3**</b>	<b>Midbrain</b>		
Pyramidal	43.4 ± 4.5	<b>53.5 ± 4.1</b>	AV thalamic nucleus	66.3 ± 4.4	<b>62.1 ± 2.7</b>
Radiatum	49.5 ± 3.6	<b>58.2 ± 3.6</b>	Gray sup colliculus	57.8 ± 2.9	<b>72.9 ± 4.5*</b>
Dentate gyrus	108.1 ± 4.5	<b>129.3 ± 5.0*</b>	Opt sup colliculus	28.8 ± 5.3	<b>31.3 ± 6.2</b>
Granular	34.4 ± 2.5	<b>46.4 ± 2.0*</b>	<b>Cerebral cortex</b>		
Molecular	106.3 ± 8.8	<b>114.9 ± 7.1</b>	Cingulate	11.2 ± 2.3	<b>17.9 ± 1.6*</b>
Polimorphic	74.9 ± 5.5	<b>79.7 ± 4.2</b>	Ectorhinal	10.0 ± 2.1	<b>14.6 ± 1.4</b>
<b>Cerebral cortex</b>			Perirhinal	6.9 ± 2.3	<b>10.7 ± 1.2</b>
Cingulate	38.2 ± 1.0	<b>36.1 ± 2.1</b>	Motor		
Ectorhinal	58.5 ± 5.5	<b>54.6 ± 2.9</b>	Layer I-II	19.6 ± 2.6	<b>26.5 ± 2.1</b>
Entorhinal	51.4 ± 4.6	<b>47.6 ± 3.7</b>	Layer V-VI	12.7 ± 3.0	<b>21.8 ± 2.4*</b>
Perirhinal	55.2 ± 4.7	<b>54.6 ± 3.0</b>	Somatosensory		
Motor	39.5 ± 3.1	<b>36.9 ± 1.3</b>	Layer I-II	22.9 ± 1.1	<b>29.7 ± 2.5</b>
Somatosensory	43.7 ± 2.6	<b>43.9 ± 2.6</b>	Layer V-VI	12.2 ± 2.0	<b>20.3 ± 2.5*</b>
<b>Basal ganglia/cholinergic forebrain</b>			<b>Basal ganglia/cholinergic forebrain</b>		
Striatum	62.1 ± 6.1	<b>63.8 ± 3.2</b>	Striatum	8.2 ± 1.9	<b>10.0 ± 1.5</b>
Globus pallidus	5.0 ± 0.7	<b>3.3 ± 0.5</b>	Medial septum	30.1 ± 1.7	<b>31.2 ± 3.6</b>
NBM	5.4 ± 1.4	<b>4.5 ± 0.7</b>	NBM	7.2 ± 0.6	<b>3.1 ± 0.4***</b>

Data are mean ± S.E. M values of aCSF (n = 7) and SAP (n = 9) treated rats.

\* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.001 when compared to aCSF group.

**Table S6.** Absolute intensity of lipid species in organotypic cultures after treatments in both positive and negative ion mode.

Assignment	Cal <i>m/z</i>	Exp <i>m/z</i>	Intensity (u.a.)			
			VEHICLE	CARBACHOL	CAR+SCOP	CAR+PIR
<b>Positive ion mode</b>						
LPC (16:0) + H <sup>+</sup>	496.3398	496.3379	1.71·10 <sup>9</sup> ± 224629	<b>4.7·10<sup>9</sup></b> ± <b>6·10<sup>5</sup>*a</b>	3.1·10 <sup>9</sup> ± 1·10 <sup>5</sup>	<b>4.25E+09</b> ± <b>6·10<sup>5</sup>*b</b>
LPC (16:1) + H <sup>+</sup>	494.3241	494.3270	3809. ± 461	<b>11696.00</b> ± <b>2506*a</b>	5400.00 ± 1336	<b>7250.00</b> ± <b>2101</b>
LPC (18:0) + H <sup>+</sup>	524.3744	524.3711	910345 ± 166700	<b>5.52·10<sup>9</sup></b> ± <b>5·10<sup>5</sup>*a</b>	4. ·10 <sup>9</sup> ± 2·10 <sup>5</sup>	<b>5.2·10<sup>9</sup></b> ± <b>6·10<sup>5</sup>*b</b>
LPC (O-18:0) + H <sup>+</sup>	508.3761	508.3788	6580 ± 864	<b>18654</b> ± <b>2098**a</b>	10133 ± 840	<b>15956</b> ± <b>1373*b</b>
LPC (O-18:1) + H <sup>+</sup>	506.3594	506.3605	8.84·10 <sup>4</sup> ± 13851	<b>1.39·10<sup>9</sup></b> ± <b>2·10<sup>5</sup>*a</b>	9.5·10 <sup>5</sup> ± 1·10 <sup>5</sup>	<b>1.4·10<sup>9</sup></b> ± <b>1·10<sup>5</sup>*b</b>
PC (36:4) + H <sup>+</sup>	782.5694	782.5727	9.29·10 <sup>9</sup> ± 1·10 <sup>9</sup>	<b>5.89·10<sup>9</sup></b> ± <b>3·10<sup>5</sup>*a</b>	7.1·10 <sup>9</sup> ± 2·10 <sup>5</sup>	<b>5.8·10<sup>9</sup></b> ± <b>2·10<sup>5</sup>**b</b>
PC (O-36:4) + H <sup>+</sup>	768.5902	768.5943	173714 ± 7706	<b>54424</b> ± <b>9721*a</b>	146795 ± 6801	<b>69580</b> ± <b>12002*b</b>
PC (36:5) + Na <sup>+</sup>	802.5357	802.5401	44361 ± 1268	<b>23056</b> ± <b>3204</b>	35767 ± 6284	<b>14701</b> ± <b>3088**b</b>
PC (38:5) + H <sup>+</sup>	808.5851	808.5861	761567 ± 42629	<b>526654</b> ± <b>21651*a</b>	700222 ± 63349	<b>568492</b> ± <b>48686</b>
PC (38:6) + H <sup>+</sup>	806.5694	806.5742	764787 ± 81976	<b>349308</b> ± <b>23788**a</b>	481258 ± 32195	<b>349138</b> ± <b>4729*b</b>
PC(38:7) + H <sup>+</sup>	804.5565	804.5538	597052 ± 100617	<b>270280</b> ± <b>26512*a</b>	402153 ± 59147	<b>248105</b> ± <b>40459*b</b>
PC(O-38:7) + H <sup>+</sup>	790.5745	790.5795	63971 ± 5613	<b>26141</b> ± <b>4941*a</b>	64351 ± 9306	<b>30403</b> ± <b>4465</b>
PC(40:7) + Na <sup>+</sup> /PC (36:4) + H <sup>+</sup>	832.5851	832.5851	288228 ± 24796*	<b>197092</b> ± <b>19490</b>	282757 ± 21872	<b>185810</b> ± <b>35558</b>
<b>Negative ion mode</b>						
LPC (O-18:0) -CH <sub>3</sub>	508.3409	508.3418	3997 ± 1106	<b>18226</b> ± <b>1697*a</b>	11564 ± 1505	<b>20301</b> ± <b>3041**b</b>

The maximal peak in negative ion mode, PI (20:4/18:0), changed with treatments. Data are mean ± S.E.M values of absolute intensity of VEHICLE (n = 6), CARBACHOL (n = 4), CAR+SCOP: Carbachol+Scopolamine (n = 4), and CAR+PIR: Carbachol+Pirenzepine (n = 4) of absolute intensity. \*p < 0.05, \*\*p < 0.01. **a\*** when compared VEHICLE vs CARBACHOL. **b\*** when compared VEHICLE vs CAR+PIR. PC: phosphatidylcholine; LPC: phosphatidylcholine; Cal: calculated; Exp: experimental.